Gastrointestinal Cancer | Specialty

Higher Vitamin D Levels Improve Survival for Patients With mCRC

January 12th 2015

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.

Ramucirumab Improves Survival in Second-Line mCRC

January 12th 2015

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.

Lanreotide Approval Opens Doors for Treatment of GEP-NETs

January 3rd 2015

Lanreotide (Somatuline Depot), which was recently approved by the FDA, is the first and only anti-tumor therapy with a statistically significant progression-free survival benefit in the treatment of adults patients with gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs).

Expanded RAS Mutation Testing in mCRC

January 1st 2015

2014 Year in Review

January 1st 2015

Minimally Invasive Esophagectomy Improves Outcomes, But Remains Underutilized

December 14th 2014

Surgery remains the most effective curative treatment for esophageal cancer. Yet, many eligible patients do not undergo esophagectomy.

From Bedside to Bench

November 29th 2014

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer

November 19th 2014

The FDA has granted MM-398 (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer

Experts Emphasize Therapy Options, Expanded Mutation Testing in mCRC

November 18th 2014

Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding

Dr. Holcombe on the Utility of Stool DNA Test for Colon Cancer

November 17th 2014

Randall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses key takeaways for a practicing oncologist regarding the stool DNA test for colon cancer.

Making Strides With Microspheres: Trial Aims to Extend SIR-Spheres Usage in CRC Liver Metastases

November 12th 2014

The 5-year survival rate for patients with metastatic colorectal cancer (CRC) remains dismal.

Proactively Managing Treatment-Related Adverse Events in Advanced Colorectal Cancer

November 10th 2014

As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.

Side Effect Management With Regorafenib in mCRC

November 8th 2014

Second- and Third-Line Therapies in mCRC

November 8th 2014

Goals of Therapy in Metastatic CRC

November 8th 2014

Selecting First-line Treatment in mCRC

November 8th 2014

Latest News & Insight: November 7, 2014

November 8th 2014

Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel

November 7th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

FDA Approves Ramucirumab Plus Paclitaxel for Advanced Gastric Cancer

November 5th 2014

The FDA has approved the combination of ramucirumab and paclitaxel as a treatment for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Collaboration Accelerates KRAS Inhibitor Development

November 4th 2014

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.